Scholar Rock Holding Corporation
NASDAQ:SRRKBiotechnology
+$0.49 today
- Market cap
- $5.86B
- Beta
- 0.69
- P/E (TTM)
- -14.8
- EPS (TTM)
- -$3.21
Volume 2.77M
Average 1.46M
SRRK Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Scholar Rock Holding CorporationNASDAQ: SRRK
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $54.13M rose 7.2% year over year, ahead of the -0.0% change in trailing-twelve-month research & development. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +7.2% holds above the trailing-twelve-month pace of -0.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 208.44M USD
- Year-over-year change
- +14.1%
- 4-year CAGR
- +17.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 208.44M | +14.1% |
| FY2024 | 2024-12-31 | 182.61M | +53.4% |
| FY2023 | 2023-12-31 | 119.06M | -4.3% |
| FY2022 | 2022-12-31 | 124.44M | +14.7% |
| FY2021 | 2021-12-31 | 108.47M | — |
Research & Development vs competitors
How SRRK compares with its peers on the latest reported figures
- SRRK's LTM Sep 2026 research & development of $211.05M is the 8th highest of the 11 companies compared; the peer median is $420.99M.
- Its year-over-year change of -0.0% is the 9th highest of 11, against a peer median of +13.4%.
- Research & development amounts to 37026.5% of revenue for SRRK, versus a peer median of 96.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $902.58M | -34.5% | +20.2% | 41.3% | |
| LTM Jun 2026 | $530.96M | +12.1% | +6.1% | 74.5% | |
| LTM Jun 2026 | $445.71M | +17.2% | +40.8% | — | |
| LTM Jun 2026 | $433.31M | -14.7% | -11.3% | 43.0% | |
| LTM Jun 2026 | $408.66M | +3.1% | +9.5% | 261.9% | |
| LTM Sep 2026 | $371.08M | +36.1% | +41.7% | — | |
| LTM Sep 2026 | $211.05M | -0.0% | +18.8% | 37026.5% | |
| LTM Sep 2026 | $165.37M | +14.7% | +41.0% | — | |
| LTM Mar 2026 | $144.07M | +45.7% | +21.0% | 449.1% | |
| LTM Mar 2026 | $114.57M | +28.4% | +7.1% | 572.9% | |
| Peer median (excluding SRRK) | $420.99M | +13.4% | +14.9% | 96.2% | |
Competitors are the stored peer set for SRRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.82M | 33.19M | 0 | 0 | 0 |
| Cost of Revenue | 108.47M | 123.04M | 2.84M | 1.94M | 208.44M |
| Gross Profit | (89.65M) | (89.85M) | (2.84M) | (1.94M) | (208.44M) |
| Gross Margin | -476.5% | -270.7% | — | — | — |
| Research & Development | 108.47M | 124.44M | 119.06M | 182.61M | 208.44M |
| Selling, General & Admin | 40.27M | 42.62M | 49.4M | 67.5M | 176.21M |
| Operating Expenses | 40.27M | 44.52M | 168.45M | 250.12M | 176.21M |
| Depreciation & Amortization | 2.63M | 2.99M | 2.84M | 1.94M | 1.66M |
| EBITDA | (129.17M) | (129.48M) | (162.95M) | (237.52M) | (369.39M) |
| EBITDA Margin | -686.5% | -390.1% | — | — | — |
| Operating Income | (129.92M) | (134.37M) | (171.3M) | (252.05M) | (384.65M) |
| Operating Margin | -690.5% | -404.8% | — | — | — |
| Interest Income | 0 | 0 | 0 | 12.68M | 13.9M |
| Interest Expense | 0 | 0 | 0 | 6.84M | 6.89M |
| Other Income / Expenses | (1.88M) | (132K) | 5.51M | 5.76M | 6.71M |
| Income Before Tax | (131.8M) | (134.5M) | (165.79M) | (246.29M) | (377.94M) |
| Pre-Tax Margin | -700.5% | -405.2% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (131.8M) | (134.5M) | (165.79M) | (246.29M) | (377.94M) |
| Net Margin | -700.5% | -405.2% | — | — | — |
| EPS (Basic) | (3.59) | (2.21) | (1.99) | (2.47) | (3.29) |
| EPS (Diluted) | (3.59) | (2.21) | (1.99) | (2.47) | (3.29) |
| Weighted Avg Shares | 36.71M | 59.61M | 75.98M | 99.84M | 114.7M |
| Weighted Avg Shares (Diluted) | 36.71M | 59.61M | 75.98M | 99.84M | 114.7M |
Scholar Rock Holding Corporation
NASDAQ:SRRK
Intrinsic Alpha fair value
Locked
Current Price
$48.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.